Dimethyl Sulfoxide
Apexbio Technology LLC BMH-21(Synonyms: BMH21, BMH 21, CID 46835406, RNA polymerase I inhibitor BMH-21, RNA Pol I inhibitor BMH-21), 10mM (in 1mL DMSO), CAS: 896705-16-1.
BMH-21 (CAS 896705-16-1) is a planar heterocyclic small molecule DNA intercalator that selectively inhibits RNA polymerase I (Pol I)-mediated transcription It preferentially inserts into GC-rich double-stranded DNA regions leading to Pol I blockade and subsequent degradation of its catalytic subunit RPA194 BMH-21 exhibits cytotoxic activity across various human cancer cell lines independently of the p53 status disrupting nucleolar integrity and RNA synthesis Furthermore BMH-21 promotes p53 expression in epithelial compartments of human prostate tissues demonstrating tissue permeability and highlighting its applicability in anticancer research
Apexbio Technology LLC vinblastine 865-21-4 10mM (in 1mL DMSO)
Vinblastine is a naturally-derived alkaloid isolated from Catharanthus roseus It functions as a microtubule inhibitor by binding specifically to tubulin disrupting microtubule polymerization and thereby arresting mitosis at metaphase Due to this mechanism vinblastine is widely investigated for antitumor activities and is commonly employed in biomedical research to study cell division cytoskeletal dynamics and therapeutic interventions in oncology Vinblastine should be stored under sealed dry and cool conditions to maintain molecular integrity and biological activity
Apexbio Technology LLC Regorafenib 755037-03-7 10mM (in 1mL DMSO)
Regorafenib (CAS 755037-03-7) is an orally bioavailable inhibitor targeting multiple receptor tyrosine kinases (RTKs) such as VEGFR1/2/3 PDGFR Kit RET Raf-1 B-RAF and B-RAFV600E By impeding kinase phosphorylation (IC50 values ranging from approximately 1 5 46 nM) regorafenib disrupts signaling pathways associated with angiogenesis tumor cell proliferation and metastasis Preclinically regorafenib inhibited VEGFR2 phosphorylation (IC50 3 nM) and reduced VEGF-induced endothelial cell proliferation in vitro In rodent tumor xenograft models it demonstrated dose-dependent tumor growth suppression and antimetastatic potential supporting its utility for oncology research
Apexbio Technology LLC Acetaminophen 103-90-2 10mM (in 1mL DMSO)
Acetaminophen (paracetamol) is a cyclooxygenase-2 (COX-2) inhibitor widely employed in biomedical studies for investigating analgesic and antipyretic mechanisms Its inhibition of COX-2 enzyme activity occurs with an IC50 of approximately 25 8 M Experimental use includes inducing cellular hepatotoxicity models where acetaminophen exposure triggers glutathione depletion impaired glutathione peroxidase activity and ferroptosis-mediated cell death This makes acetaminophen useful in examining oxidative stress hepatic cell injury and associated cellular response mechanisms in vitro and in animal studies Additionally acetaminophen-mediated toxicity is applicable in screening protective agents or evaluating ferroptosis inhibitors in pharmacological research
Apexbio Technology LLC SP 600125 129-56-6 10mM (in 1mL DMSO)
SP 600125 (CAS 129-56-6) is a selective reversible ATP-competitive inhibitor of c-Jun N-terminal kinase (JNK) with reported IC50 values of 40 nM for JNK1 and JNK2 and 90 nM for JNK3 Initially identified via GST-c-Jun substrate and recombinant human JNK2 screening assays SP 600125 demonstrates marked specificity being approximately 300-fold more selective toward JNK isoforms compared to ERK1 and p38-2 kinases In cellular assays SP 600125 effectively suppresses JNK-mediated phosphorylation of c-Jun and attenuates expression of IL-2 IFN- and TNF- It is widely utilized in inflammation and signal transduction research
Apexbio Technology LLC LMK 235 1418033-25-6 10mM (in 1mL DMSO)
LMK 235 (CAS 1418033-25-6) is a histone deacetylase (HDAC) inhibitor exhibiting preferential selectivity against HDAC4 and HDAC5 isoforms HDAC enzymes (EC 3 5 1 98) catalyze the removal of acetyl groups from lysine residues on histone proteins influencing DNA-histone interactions and gene expression In vitro LMK 235 demonstrates potent inhibition at nanomolar concentrations against HDAC4/5 and notable cytotoxic effects toward multiple cancer cell lines including A2780 Cal27 Kyse510 and MDA-MB231 In animal studies LMK 235 enhances the antitumor efficacy of cytarabine suggesting applications in overcoming chemoresistance in leukemia models Currently LMK 235 remains under preclinical investigation
Apexbio Technology LLC LY2835219 1231930-82-7 10mM (in 1mL DMSO)
LY2835219 (CAS 1231930-82-7) is a selective orally bioavailable inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6) It targets CDK4 and CDK6 with reported IC50 values of 2 nM and 10 nM respectively thereby reducing phosphorylation of the retinoblastoma protein (Rb) This mechanism leads to cell-cycle arrest during the G1 phase and subsequent inhibition of tumor cell proliferation LY2835219 demonstrates the capacity to cross the blood-brain barrier indicating its potential utility in research involving primary or metastatic intracranial tumors
Apexbio Technology LLC Topotecan 123948-87-8 10mM (in 1mL DMSO)
Topotecan (CAS 123948-87-8) a semisynthetic derivative of camptothecin functions by selectively inhibiting topoisomerase I This inhibition stabilizes enzyme-DNA cleavage complexes disrupting DNA replication and transcription processes essential for tumor cell proliferation In preclinical studies topotecan demonstrated antitumor activity in mouse models of leukemia (P388) Lewis lung carcinoma B16 melanoma and human colon adenocarcinoma xenograft HT-29 Its toxicity primarily affecting rapidly proliferating tissues such as bone marrow and gastrointestinal epithelium was concentration-dependent and reversible Topotecan is employed extensively as a research tool in oncology studies focusing on DNA-topoisomerase interactions and targeting solid tumor growth
Apexbio Technology LLC CFI-400945 1338806-73-7 10mM (in 1mL DMSO)
CFI-400945 (CAS 1338806-73-7) is an orally bioavailable inhibitor specifically targeting polo-like kinase 4 (PLK4) a member of the polo-like kinase family involved in centriole duplication and cell cycle control By competitively inhibiting ATP binding to PLK4 CFI-400945 potently suppresses PLK4 catalytic activity (IC50 2 8 nM) and blocks PLK4 autophosphorylation in cellular assays (EC50 12 3 nM) The compound exhibits high selectivity against other polo-like kinases and demonstrates antiproliferative activity in various cancer cell lines Thus CFI-400945 is applied in cancer biology research particularly for studying centrosome regulation and tumor growth inhibition
Apexbio Technology LLC CVT-313 199986-75-9 10mM (in 1mL DMSO)
CVT-313 (CAS 199986-75-9) is a potent inhibitor of cyclin-dependent kinase 2 (CDK2) an enzyme essential for G1/S transition during cell cycle progression By targeting CDK2 CVT-313 effectively reduces hyperphosphorylation of retinoblastoma protein (Rb) leading to cell cycle arrest at the G1/S boundary In vitro studies with MRC-5 fibroblasts demonstrated significant growth inhibition Additionally CVT-313 induces apoptosis in diffuse large B-cell lymphoma by diminishing phosphorylation of Rb at T821 and downregulating anti-apoptotic protein Mcl-1 In animal models of arterial restenosis CVT-313 significantly reduces neointimal proliferation indicating potential utility for proliferative disorders research
Apexbio Technology LLC Oseltamivir 196618-13-0 10mM (in 1mL DMSO)
Oseltamivir is a neuraminidase inhibitor targeting influenza virus replication It functions as a prodrug metabolized into oseltamivir carboxylate by host esterases This active metabolite binds to viral neuraminidase thereby blocking cleavage of terminal -Neu5Ac residues and subsequent viral progeny release from infected host cells Oseltamivir has been widely employed in investigative studies addressing antiviral efficacy resistance mechanisms and clinical outcomes in influenza infection research The compound is frequently used in vitro to characterize neuraminidase activity inhibition typically reporting IC50 values in the low nanomolar range (approximately 0 1-5 nM) depending on the influenza viral strain and assay conditions influencing viral replication and transmission
Apexbio Technology LLC Flunixin Meglumin 42461-84-7 10mM (in 1mL DMSO)
Flunixin meglumine (CAS 42461-84-7) is a potent non-steroidal anti-inflammatory drug (NSAID) known to inhibit cyclooxygenase (COX) enzymes It exerts its biological effects primarily by blocking prostaglandin synthesis through non-selective inhibition of COX isoforms exhibiting an IC50 of approximately 1 nM Preclinical studies indicate analgesic and antipyretic properties in rodent and primate pain models Flunixin meglumine is utilized experimentally to modulate inflammatory responses particularly in veterinary models involving ischemic enteritis endotoxemia and colic
Medchemexpress LLC Puromycin 10 Mm 1 Ml In Dmso | HY-B1743-10 MM 1 ML IN
Puromycin 10 Mm 1 Ml In Dmso
Apexbio Technology LLC Salirasib 162520-00-5 10mM (in 1mL DMSO)
Salirasib (CAS 162520-00-5) chemically known as S-trans trans-farnesylthiosalicylic acid (FTS) is a synthetic inhibitor targeting Ras proteins Structurally mimicking the carboxy-terminal farnesylated cysteine found in Ras Salirasib disrupts Ras localization at the cellular membrane thereby reducing activity of H-ras K-ras and N-ras isoforms Research indicates that Salirasib reduces Ras protein levels by approximately 50% at concentrations of 25 50 M in Panc-1 pancreatic cancer cells In xenograft models it exhibits tumor growth inhibition alone and synergistically with gemcitabine Clinical phase I studies support its continued investigation in solid-tumor therapy recommending a dose of 600 mg/day